Ferguson Shapiro LLC Has $294,000 Position in Johnson & Johnson $JNJ

Ferguson Shapiro LLC reduced its stake in shares of Johnson & Johnson (NYSE:JNJ) by 16.4% in the 2nd quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 1,923 shares of the company’s stock after selling 376 shares during the quarter. Ferguson Shapiro LLC’s holdings in Johnson & Johnson were worth $294,000 as of its most recent filing with the SEC.

Several other institutional investors have also made changes to their positions in the stock. Strategic Financial Services Inc. boosted its holdings in shares of Johnson & Johnson by 1.7% during the second quarter. Strategic Financial Services Inc. now owns 9,443 shares of the company’s stock worth $1,442,000 after purchasing an additional 154 shares during the period. New York Life Investment Management LLC boosted its holdings in shares of Johnson & Johnson by 1.7% during the second quarter. New York Life Investment Management LLC now owns 332,631 shares of the company’s stock worth $50,809,000 after purchasing an additional 5,544 shares during the period. Integral Investment Advisors Inc. boosted its holdings in shares of Johnson & Johnson by 1.6% during the second quarter. Integral Investment Advisors Inc. now owns 16,908 shares of the company’s stock worth $2,583,000 after purchasing an additional 266 shares during the period. Howard Capital Management Inc. boosted its holdings in shares of Johnson & Johnson by 10.3% during the second quarter. Howard Capital Management Inc. now owns 18,203 shares of the company’s stock worth $2,781,000 after purchasing an additional 1,693 shares during the period. Finally, Purkiss Capital Advisors LLC boosted its holdings in shares of Johnson & Johnson by 4.5% during the second quarter. Purkiss Capital Advisors LLC now owns 14,289 shares of the company’s stock worth $2,183,000 after purchasing an additional 610 shares during the period. 69.55% of the stock is currently owned by institutional investors and hedge funds.

Johnson & Johnson Price Performance

Shares of Johnson & Johnson stock opened at $186.94 on Wednesday. The firm has a fifty day simple moving average of $182.72 and a 200-day simple moving average of $166.92. The company has a current ratio of 1.07, a quick ratio of 0.80 and a debt-to-equity ratio of 0.50. Johnson & Johnson has a 1-year low of $140.68 and a 1-year high of $194.48. The stock has a market capitalization of $450.40 billion, a price-to-earnings ratio of 18.04, a PEG ratio of 2.24 and a beta of 0.40.

Johnson & Johnson (NYSE:JNJ) last issued its quarterly earnings data on Wednesday, August 30th. The company reported $2.26 earnings per share for the quarter. Johnson & Johnson had a net margin of 27.26% and a return on equity of 32.73%. The business had revenue of $24.02 billion during the quarter. On average, sell-side analysts expect that Johnson & Johnson will post 10.58 earnings per share for the current year.

Johnson & Johnson Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 9th. Stockholders of record on Tuesday, November 25th will be paid a $1.30 dividend. This represents a $5.20 dividend on an annualized basis and a dividend yield of 2.8%. The ex-dividend date is Tuesday, November 25th. Johnson & Johnson’s payout ratio is presently 50.19%.

Insider Buying and Selling at Johnson & Johnson

In other news, EVP Jennifer L. Taubert sold 56,471 shares of the business’s stock in a transaction on Thursday, September 4th. The shares were sold at an average price of $177.81, for a total value of $10,041,108.51. Following the completion of the sale, the executive vice president directly owned 178,013 shares in the company, valued at approximately $31,652,491.53. The trade was a 24.08% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders own 0.16% of the company’s stock.

Analyst Upgrades and Downgrades

Several analysts recently commented on the stock. Wall Street Zen upgraded shares of Johnson & Johnson from a “hold” rating to a “buy” rating in a report on Saturday, September 13th. Citigroup raised their price objective on shares of Johnson & Johnson from $213.00 to $215.00 and gave the company a “buy” rating in a research report on Wednesday, October 15th. Argus set a $210.00 price objective on shares of Johnson & Johnson in a research report on Wednesday, October 15th. Johnson Rice set a $190.00 price objective on shares of Johnson & Johnson and gave the company a “hold” rating in a research report on Wednesday, October 22nd. Finally, Wells Fargo & Company set a $212.00 price objective on shares of Johnson & Johnson and gave the company an “overweight” rating in a research report on Friday, October 3rd. Three research analysts have rated the stock with a Strong Buy rating, fourteen have issued a Buy rating and nine have given a Hold rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $199.05.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.